Disinfection specialist PuriCore has appointed Alex Martin as chief executive. effective 1 June.

Martin will replace current chief executive https://healthinvestor.co.uk/wp-content/uploads/2021/11/logo-social-1.png Ashton, who announced his intention to retire in October 2014.

Martin has held numerous senior positions at pharmaceutical firms. For instance he was chief executive of Affectis Pharmaceuticals, chief business officer at Bioxell Pharma and chief operating officer at Intercept Pharmaceuticals.

Most recently, Martin was president at Latin American pharmaceutical firm moksha8.

PuriCore non-executive chairman Charles Spicer said: “We are delighted to welcome Alex to PuriCore at an important time in the company’s development. We are confident that with his broad operational background and leadership experience across a range of companies, he is well suited to enable us to capitalise on the opportunities identified in our strategic and operational review as well as to identify potential new ones.”